Proteome Sciences (PRM)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 347.1 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 52.1 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | TTM | 2012E | 2013E | CAGR / Avg | |
| Revenue | £m | ||||||||||
| Operating Profit | £m | ||||||||||
| Net Profit | £m | ||||||||||
| EPS Reported | p | ||||||||||
| EPS Normalised | p | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | p | ||||||||||
| Capex ps | p | ||||||||||
| Free Cashflow ps | p | ||||||||||
| Dividends | |||||||||||
| Dividend ps | p | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | £m | ||||||||||
| Working Capital | £m | ||||||||||
| Net Fixed Assets | £m | ||||||||||
| Net Debt | £m | ||||||||||
| Book Value | £m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | p | -2.5% | |||||||||
FINANCIAL BRIEF: For the six months ended 30 June 2012, Proteome Sciences plc revenues increased 44% to L893K. Net loss decreased 36% to L1.2M. Revenues reflect Licenses/Sales/Services increase of 38% to L502K, Grant services increase of 53% to L391K. Basic Earnings per Share excluding Extraordinary Items remained flat at -L0.01. more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 30th Jun '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 0 | 0 | 0 | 1 | 0 |
Proteome Sciences plc is engaged in biomarker research and development in applied proteomics, using techniques to detect and characterize differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications. It is a Protein Biomarker Discovery Service company specializing in Proteomics and Peptidomics applications and a mass spectrometry protein company. The Company’s three geographic segments include: United Kingdom, Germany and the United States. The main focus of research is to address neurological, neurodegenerative, cardiovascular and cancer conditions and blood biomarkers in stroke, brain damage, solid organ transplant rejection and Alzheimer’s disease. The company’s subsidiaries include Proteome Sciences R&D Verwaltungs GmbH, Proteome Sciences R&D GmbH & Co. KG, Xzillion GmbH & Co. KG, Proteome Sciences, Inc., Veri-Q Inc. and Phenomics Limited.
Directors: Christopher Pearce (CEO) , James Malthouse (Fin. Dir.) , Ian Pike (COO) , Malcolm Ward (CTO) , Hans-Dieter Zucht (CTO) , Glenn Barney (VP-Bus.Dev.) , Josef Schwarz (Other) , Rainer Voegeli (Other) ,
No. of Employees: 38 No. of Shareholders: n/a
| Last Annual | December 31st, 2011 |
| Last Interim | June 30th, 2012 |
| Shares in Issue | 192,498,500 |
| Free Float | 150.0m (77.9%) |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | FTSE Aim All Share, |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | Coveham House Downside Bridge Road, COBHAM, KT11 3EP, United Kingdom |
| Web | http://www.proteomics.com/ |
| Phone | +44 1932 865065 |
| Contact | J.L. Malthouse (Secy.) |
| Registrar | Capita Registrars (Kent) |
| Auditors | Deloitte LLP |
| 19th Apr | Trading Update |
| 2nd Apr | Block admission return |
| 18th Mar | Developments in Alzheimers Disease |
| 22nd Jan | Trading Statement |
| 31st Dec '12 | CK1D Update |
| 3rd Dec '12 | Holding(s) in Company |
Recent ↓
